Altimmune Secures $281.5M in Offerings, Doubles Authorized Shares Amidst Increased Burn

summarizeSummary

Altimmune reported a Q1 net loss of $22.6M and a cash burn of $20.9M, but significantly bolstered its cash position by raising $281.5M through recent offerings and increased authorized shares to 400M, extending its cash runway for critical clinical trials.

check_boxKey Events

• Significant Capital Raises

  The company completed a Registered Direct Offering (RDO) in January 2026, raising approximately $70.3 million in net proceeds. This was followed by an underwritten public offering in April 2026, which generated an additional $211.2 million in net proceeds, totaling $281.5 million in recent capital infusions.

• Substantial Share Dilution

  The January RDO involved 12.4 million common shares and 4.6 million pre-funded warrants (exercised in Feb 2026). The April offering issued 75 million shares (common stock and pre-funded warrants) along with 75 million accompanying common stock warrants. This represents a significant increase in outstanding shares and potential future dilution if warrants are exercised.

• Increased Authorized Shares

  Shareholders approved an amendment on April 16, 2026, to increase the number of authorized common stock from 200 million to 400 million shares, providing substantial headroom for future equity financing.

• Extended Cash Runway

  As of March 31, 2026, cash, cash equivalents, and short-term investments totaled $331.6 million. Including the April offering proceeds, the company believes it has sufficient capital to fund operations for at least a twelve-month period, crucial for its ongoing clinical programs.

auto_awesomeAnalysis

This quarterly report details significant capital raises and increased authorized shares, which are critical for Altimmune's operations as a clinical-stage biopharmaceutical company. The substantial dilution from these offerings is a key concern for existing shareholders, but the capital infusion provides a crucial cash runway for at least 12 months, enabling the company to advance its pivotal Phase 3 MASH trial for pemvidutide. The increased authorized shares also signal potential for further future dilution.